Tiantan Biopharma's 2024 net profit soars 39%

Beijing Tiantan Biological Products Corp (SSE:600161) reported a 39.42% year-on-year surge in net profit attributable to shareholders, reaching ¥154.74 million in 2024. This robust growth was driven by a 16.47% increase in operating income, which totaled ¥603.35 million, fueled by higher product sales volumes and price increases. Operating profit also climbed significantly, rising 41.98% to ¥256.28 million. The company's plasma collection efforts yielded positive results, with a 15.15% increase to 2,781 tons across its 85 plasma collection centers. Basic earnings per share rose to ¥0.78 from ¥0.56 the previous year. These preliminary figures are unaudited and subject to change upon finalization of the 2024 annual report.